Market Research Logo

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. There are two types of heart failure including systolic heart failure (left ventricle loses its ability to contract normally) and diastolic heart failure (left ventricle loses its ability to relax normally). The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 13, 31, 21, 2, 61 and 14 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 4 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Congestive Heart Failure (Heart Failure) - Overview
Congestive Heart Failure (Heart Failure) - Therapeutics Development
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development
Congestive Heart Failure (Heart Failure) - Drug Profiles
Congestive Heart Failure (Heart Failure) - Dormant Projects
Congestive Heart Failure (Heart Failure) - Discontinued Products
Congestive Heart Failure (Heart Failure) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Companies, H2 2018 (Contd..5), H2 2018
Products under Development by Companies, H2 2018 (Contd..6), H2 2018
Products under Development by Companies, H2 2018 (Contd..7), H2 2018
Products under Development by Companies, H2 2018 (Contd..8), H2 2018
Products under Development by Universities/Institutes, H2 2018
Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..3), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..3), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Adrenomed AG, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Arbor Pharmaceuticals LLC, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Astellas Pharma Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by BlueRock Therapeutics, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Co, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by C&C BioPharma LLC, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Cells for Cells SA, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Galenica Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Immunwork Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Intra-Cellular Therapies Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by KBP BioSciences Co Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Madeleine Pharmaceuticals Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Miragen Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Moderna Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by N-Gene Research Laboratories Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Otsuka Holdings Co Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Oxstem Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corp, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Ribomic Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Shin Poong PharmCo Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by XyloCor Therapeutics Inc, H2 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..2), H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..3), H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..4), H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..5), H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..6), H2 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2018 (Contd..7), H2 2018
Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2018
Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2018 (Contd..1), H2 2018
List of Figures
Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report